A PHASE-II, OPEN-LABEL STUDY TO EVALUATE 2 DIFFERENT SCHEDULES FOR INTEGRATING FILGRASTIM (RECOMBINANT-METHIONYL HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR) AS ADJUVANT THERAPY IN THE TREATMENT OF PATIENTS WITH HODGKINS LYMPHOMA RECEIVING MOPP ABV HYBRID CHEMOTHERAPY/

CANTIN G LESPERANCE B YELLE L BELANGER D CANTIN G BERGERON M DESJARDINS L OUELLET P DUFRESNE J BEAUREGARD P LEPINE M LACROIX L COUTURE F GYGER M

G. Cantin et al., A PHASE-II, OPEN-LABEL STUDY TO EVALUATE 2 DIFFERENT SCHEDULES FOR INTEGRATING FILGRASTIM (RECOMBINANT-METHIONYL HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR) AS ADJUVANT THERAPY IN THE TREATMENT OF PATIENTS WITH HODGKINS LYMPHOMA RECEIVING MOPP ABV HYBRID CHEMOTHERAPY/, Blood, 86(10), 1995, pp. 197-197

NO

Hematology

Blood → ACNP

00064971

86

10

1995

1

197 - 197

ISI

0006-4971(1995)86:10<197:APOSTE>2.0.ZU;2-G